Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: Breast density is recognized as a well-established risk factor for breast cancer, influencing screening recommendations. While quantitative measures of breast density have been developed to address limitations of qualitative measures, the role of racial differences in quantitative measures and their effect on breast cancer risk, especially in Black women, remains unclear. Additionally, while background parenchymal enhancement (BPE) is an established as a predictor of breast cancer risk, no research has been conducted to investigate whether the impact of BPE varies by race or ethnicity. This perspective reviews existing data on BPE, specifically its relationship with breast density and breast cancer risk and emphasizes the need for further investigation in Black women.

Discussion: Current supplemental screening methods are heavily reliant on qualitative breast density assessments, which may disadvantage Black women. Although BPE has been significantly associated with breast cancer risk independent of breast density, no studies were found that explored the relationship between BPE and breast cancer risk in Black women.

Conclusion: The limited data on absolute quantitative density measures, such as dense volume, which could improve screening practices, is highlighted in this review. While BPE is well-established as a breast cancer risk factor, further research is needed to investigate racial differences in BPE and its association with breast cancer risk, particularly among Black women.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2025.07.009DOI Listing

Publication Analysis

Top Keywords

breast cancer
36
cancer risk
28
breast density
24
breast
15
risk black
12
black women
12
cancer
9
background parenchymal
8
parenchymal enhancement
8
risk
8

Similar Publications

The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor down-regulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor.

View Article and Find Full Text PDF

Nitric oxide (NO) is a multifunctional signaling molecule in oncology, influencing tumor progression, apoptosis, and immune responses. In contrast, chlorambucil (Cbl), a DNA-alkylating chemotherapeutic, induces cytotoxicity through DNA damage. Here, we report a photoresponsive nanoparticle platform for sequential codelivery of NO and Cbl, where NO is released within 10 min of irradiation, followed by Cbl release within 30 min.

View Article and Find Full Text PDF

Paraneoplastic cerebellar degeneration (PCD) is a rare neurological disorder caused by tumor-mediated antibodies targeting the cerebellum, often leading to irreversible cerebellar damage. The most common antibody implicated in PCD is anti-Purkinje cell cytoplasmic antibody type-1, associated with malignancies such as breast, gynecological, and lung cancers. Symptoms often include dizziness, imbalance, progressive ataxia, and other cerebellar signs/symptoms, but early presentations may mimic acute vestibular syndrome, thus complicating diagnosis.

View Article and Find Full Text PDF

Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.

View Article and Find Full Text PDF